March 20th 2024
The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Concomitant Chemoradiotherapy Demonstrates Survival Benefit in Nasopharyngeal Carcinoma
March 16th 2017The addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy (CRT) achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.
Read More
Researchers Identify Criteria for Optimal Use of Adjuvant CRT in Head and Neck Cancer
March 15th 2017The number of positive lymph nodes is an appropriate selection factor in deciding adjuvant chemoradiotherapy use in some patients with locally advanced head and neck cancer, according to the results of a recent retrospective analysis .
Read More
Optimizing Patient Selection for Adjuvant CRT in Head and Neck Cancer is Key, Expert Says
March 14th 2017With the objective of identifying patients who would derive greater benefit from CRT, a recent retrospective, observational cohort study examined use and survival outcomes with adjuvant CRT in patients with resected locally advanced head and neck cancer.
Read More
Study Results for Nivolumab and Pembrolizumab in Head and Neck Cancer
February 20th 2017Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses results of studies that investigated nivolumab and pembrolizumab in head and neck cancer.
Watch
Biomarker May Predict Recurrence in HPV+ Oropharyngeal Cancer
February 16th 2017Matthew E. Spector, MD, discusses a new biomarker study which found that patients whose oropharyngeal cancer recurred had higher levels of antibodies for 2 proteins, E6 and E7, which are found in HPV-driven cancers.
Read More
Individualized Bioselection Treatment Improves Survival Rates in Laryngeal Cancer
February 16th 2017A novel approach has been developed by researchers at the University of Michigan to treating patients with advanced laryngeal cancer with the hope of improving historical survival rates of 50% to 60% in this setting.
Read More
Missing Tumor-Specific Mutations Lead to Increased Resistance to Checkpoint Inhibitors
February 10th 2017Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that acquired resistance to checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.
Read More
Expert Addresses Need for Speedier Trial Design in Anaplastic Thyroid Cancer
November 22nd 2016Immunotherapy has potential in anaplastic thyroid cancer, but it presents a challenge because of the length of time it takes to have an effect. Maria Cabanillas, MD, discusses an upcoming clinical trial that is combining immunotherapy with targeted therapy, that may offer a solution.
Read More
Immunotherapy Success Is Paving the Way for "Colder" Tumors, Allison Says
November 1st 2016James Allison, PhD, discusses exciting advancements in immunotherapy combinations, the potential synergistic effects of radiation with immunotherapies, and considerations that must be made when combining other agents with immunotherapy.
Read More
Pembrolizumab in HNSCC Only Scratches the Surface of Immunotherapy Potential, Expert Says
October 27th 2016An expert discusses the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.
Read More
Adding Immunotherapy to Head and Neck Cancer Treatment Fails to Improve PFS
October 19th 2016Adding a Toll-like receptor 8 agonist (TLR8) to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) failed to improve progression-free survival (PFS).
Read More
KRAS-Variant HNSCC Outcomes May Improve With Cetuximab
October 13th 2016Patients with head and neck cancer whose disease is associated with <em>KRAS</em> variant had significantly better progression-free survival (PFS) and overall survival (OS) when treated with the monoclonal antibody cetuximab (Erbitux), according to findings of a retrospective analysis of a randomized trial.
Read More
Fixed-Dose Pembrolizumab Yields Durable Responses in HNSCC
October 5th 2016The FDA-approved fixed dose of 200 mg of pembrolizumab administered once every 3 weeks yielded durable responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC), according to results from an expansion cohort of the phase Ib KEYNOTE-012 trial.
Read More
Ongoing Trials Studying Immunotherapy as a First-Line Treatment in Head and Neck Cancer
October 3rd 2016Barbara Ann Burtness, MD, professor of medicine, Clinical Research Program Leader, Head and Neck Cancers Program and Co-Director, Developmental Therapeutics Research Program at Yale Cancer Center, discusses the ongoing trials looking at immunotherapy as a first-line treatment in head and neck cancer.
Watch
Expert Asserts Pembrolizumab to Play Important Role in Head and Neck Cancer Treatment
August 24th 2016The FDA approval of pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma in August 2016 was extremely significant for this patient population, which previously had limited options following progression on a platinum-based chemotherapy.
Read More
Individualized Approaches Recommended to Treat Elderly Patients with Localized HNSCC, Says Porceddu
July 27th 2016Although paradigms for treating older patients with head and neck cancer are not well defined, advancements in targeted and immunotherapies and less toxic radiation regimens suggest that physicians can aim for a more individualized approach to treating this patient population.
Read More
Integrating Immunotherapy With Chemoradiation in the Treatment of Head and Neck Cancer
July 6th 2016Squamous cell carcinoma of the head and neck (SCCHN) is an immunosuppressive disease, as its patients often demonstrate immune dysregulation that correlates with poorer outcomes. Trials are underway combining chemoradiotherapy with immune checkpoint inhibitors.
Read More
Studies Show Durable Activity of Pembrolizumab in Head and Neck Cancer
June 15th 2016Pembrolizumab (Keytruda), when studied in 2 clinical trials for the treatment of patients with pretreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), showed an objective response rate (ORR) of 18%, according to findings presented at the 2016 ASCO Annual Meeting.
Read More
CAR Therapy Yields High Complete Response Rates in Adults with B-cell ALL in Phase I Trial
June 9th 2016Infusion with 19-28z chimeric antigen receptor (CAR) modified T-cells led to complete response (CR) rates of 77% to 90% and minimal residual disease (MRD)-CR rates of 68% to 70% in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL).
Read More
Nivolumab Monotherapy Improves Responses in Head and Neck Squamous Cell Carcinoma
June 9th 2016Nivolumab (Opdivo) monotherapy showed improved overall survival (OS) and objective response rates for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) compared with the investigator's choice of alternative therapy, according to data presented at the 2016 ASCO Annual Meeting.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More